Merck, through its Global Health Institute, has established a portfolio of innovative and collaborative projects for new or adapted treatments, sensitive schistosomiasis diagnostics, technologies to control transmission, and research educational approaches to strengthen health systems in developing countries.

Through the Pediatric Praziquantel Consortium program, Merck is currently engaging in a clinical Phase III study to address an unmet need in paediatric schistosomiasis, conducted in Kenya and in Ivory Coast.

“As a leading company in the fight against schistosomiasis, Merck wants to impactfully contribute to the control and elimination of the disease through sustainable innovation development” said Petra Wicklandt, Head of Corporate Affairs at Merck.

“The availability of a paediatric medication is essential to address the medical need of infected pre-school age children. Our investment today secures our future generation” said Dr. Maurice Odiere, Principal Investigator for the Phase III trial and Principal Research Officer at the Kenya Medical Research Institute, KEMRI.

Together with renowned partners, Merck is also performing drug discovery activities for potential new treatments and is collaborating for new sensitive diagnostics to improve mapping and case detection of schistosomiasis. In addition, Merck is investing into innovative technologies for vector control and clean water to control transmission. The recently announced Eisai/Merck partnership addresses this topic.

Merck complements these R&D activities by donating up to 250 million praziquantel tablets annually of the standard of care treatment to the World Health Organization.

Through all these programmes, Merck plays a leading role towards defeating schistosomiasis as a serious public health burden. Oct. 10, 2019

Distributed by African Media Agency (AMA) on behalf of Merck.

About Merck 
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.